A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.
1/5 보강
[BACKGROUND] Amino acid metabolism is integral to tumor proliferation, redox control, and immune regulation.
APA
He J, Liu X, et al. (2026). A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.. Frontiers in oncology, 16, 1754912. https://doi.org/10.3389/fonc.2026.1754912
MLA
He J, et al.. "A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.." Frontiers in oncology, vol. 16, 2026, pp. 1754912.
PMID
41836241 ↗
Abstract 한글 요약
[BACKGROUND] Amino acid metabolism is integral to tumor proliferation, redox control, and immune regulation. Yet, studies in bladder cancer have largely centered on single amino acids, leaving the broader metabolic gene network insufficiently characterized.
[METHODS] Transcriptomic and clinical data from TCGA-BLCA, GSE13507, and GSE32894 were integrated with 32 MSigDB amino acid metabolism gene sets. Differential analysis, enrichment profiling, and consensus clustering defined metabolic subtypes. WGCNA and survival filtering identified candidates for a prognostic model, which was optimized using the MIME platform. Immune features and drug sensitivities were evaluated through multiple deconvolutions and pharmacogenomic resources. Single-cell data (GSE222315) were used to trace the cellular origin of model genes. expression and function were validated in tissues and bladder cancer cell lines.
[RESULTS] A total of 144 dysregulated amino acid metabolism-related genes were identified and used to define two distinct metabolic subtypes. One subtype was marked by coordinated upregulation of glutamine, branched-chain amino acid, tryptophan, and serine metabolic programs, accompanied by higher grade and stage, significantly worse survival, and dense but functionally impaired immune infiltration. From 24 candidate genes, a 16-gene metabolic signature was constructed and consistently validated across TCGA, GSE13507, and GSE32894, showing strong and stable prognostic performance superior to several published models. High-risk group displayed activation of cell-cycle, DNA-replication, , and inflammatory-stress pathways, together with predicted sensitivity to inhibitors, DNA-damaging agents, and selected epigenetic or cytoskeletal drugs. In the IMvigor210 cohort, the high-risk group showed a greater likelihood of responding to blockade. Single-cell profiling localized signature expression predominantly to malignant epithelial cells. , a core model gene, was overexpressed in tumor tissues and cell lines, and functional assays demonstrated its role in promoting proliferation, migration, invasion, and survival of bladder cancer cells.
[CONCLUSIONS] This study highlights the central role of amino acid metabolic networks in shaping bladder cancer heterogeneity and provides a metabolically grounded framework for risk stratification and therapeutic development.
[METHODS] Transcriptomic and clinical data from TCGA-BLCA, GSE13507, and GSE32894 were integrated with 32 MSigDB amino acid metabolism gene sets. Differential analysis, enrichment profiling, and consensus clustering defined metabolic subtypes. WGCNA and survival filtering identified candidates for a prognostic model, which was optimized using the MIME platform. Immune features and drug sensitivities were evaluated through multiple deconvolutions and pharmacogenomic resources. Single-cell data (GSE222315) were used to trace the cellular origin of model genes. expression and function were validated in tissues and bladder cancer cell lines.
[RESULTS] A total of 144 dysregulated amino acid metabolism-related genes were identified and used to define two distinct metabolic subtypes. One subtype was marked by coordinated upregulation of glutamine, branched-chain amino acid, tryptophan, and serine metabolic programs, accompanied by higher grade and stage, significantly worse survival, and dense but functionally impaired immune infiltration. From 24 candidate genes, a 16-gene metabolic signature was constructed and consistently validated across TCGA, GSE13507, and GSE32894, showing strong and stable prognostic performance superior to several published models. High-risk group displayed activation of cell-cycle, DNA-replication, , and inflammatory-stress pathways, together with predicted sensitivity to inhibitors, DNA-damaging agents, and selected epigenetic or cytoskeletal drugs. In the IMvigor210 cohort, the high-risk group showed a greater likelihood of responding to blockade. Single-cell profiling localized signature expression predominantly to malignant epithelial cells. , a core model gene, was overexpressed in tumor tissues and cell lines, and functional assays demonstrated its role in promoting proliferation, migration, invasion, and survival of bladder cancer cells.
[CONCLUSIONS] This study highlights the central role of amino acid metabolic networks in shaping bladder cancer heterogeneity and provides a metabolically grounded framework for risk stratification and therapeutic development.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Zeaxanthin targets TOP2A to regulate autophagy and suppress lung cancer progression via the MAPK/ERK pathway.
- Harmine inhibits non-small cell lung cancer growth by targeting phosphodiesterase4D and inducing ferroptosis.
- A Comprehensive Assessment of the Causal Relationship Between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).
- Smart Magnetic Nanozyme for Multimodal Dynamic Regulation to Reverse Multidrug Resistance in Breast Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Integrative Molecular Insights Into Epidemiological, Genetic, and Metabolic Risk Factors of Gallbladder Cancer: Implications for Biomarkers, Therapeutic Targeting, and Future Perspectives.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab.
- Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis.
- Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
- A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.